ArticleDiscover oncology2026
Construction and validation of a prognostic risk score model for malignant mesothelioma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeMalignant mesothelioma is a rare, aggressive cancer. Although the World Health Organization (WHO) histologic subtypes–epithelioid (best prognosis), biphasic, and sarcomatoid (worst prognosis)—provide baseline stratification, architectural and molecular features (e.g., aneuploidy, immune infiltration) introduce heterogeneity not fully captured by histotype alone.
methodsUsing The Cancer Genome Atlas (TCGA) data and an independent validation cohort, we found that TNM stage was not independently prognostic after multivariable adjustment. We therefore developed a clinicomolecular model integrating transcriptomic and clinicopathological variables. Differential expression analysis of TCGA tumors identified 1,055 genes associated with poor prognosis (FDR < 0.05, |log2FC| > 1). Least absolute shrinkage and selection operator (LASSO) followed by multivariate Cox regression yielded five independent predictors: pathological subtype, receipt of pharmaceutical (systemic) therapy, and tumor expression of SPAG5, CORO1C, and SGCE. The final score was: RiskScore = 1.590 × (pathological type) − 2.258 × (pharmaceutical therapy) + 3.048 × SPAG5 + 1.652 × CORO1C + 0.908 × SGCE.
resultsIn the TCGA cohort, high-risk patients had significantly shorter overall survival (log-rank p < 0.001), and time-dependent ROC AUCs exceeded 0.70 at 1–5 years. In the validation cohort, the RiskScore significantly stratified overall survival (log-rank p < 0.001) and demonstrated superior predictive accuracy over both TNM staging and the established European Organization for Research and Treatment of Cancer (EORTC) prognostic score.
conclusionThis clinicomolecular model provides prognostic discrimination superior to TNM stage and EORTC score, offering a robust tool for risk-stratified management of mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.